Combinational Chemotherapy and Photothermal Therapy Using a Gold Nanorod Platform for Cancer Treatment

Shukla, Nutan; Singh, Baljinder; Kim, Ho‐Joong; Park, Myoung‐Hwan; Kim, Kibeom

doi:10.1002/ppsc.202000099

Cited by 29 publications

(18 citation statements)

References 128 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The generated heat can provide photothermal therapy for cancer treatment and/or trigger anti-cancer drug release for chemotherapy when gold nanorods serve as a drug carrier [ 46 ]. In short, gold nanorods can be applied for cancer treatment in phototherapy, cellular imaging, drug transport, and combined therapy (e.g., phototherapy and chemotherapy) [ 47 , 48 ].…”

Section: Gold Nanostructures For Cancer Treatmentmentioning

confidence: 99%

Engineering Gold Nanostructures for Cancer Treatment: Spherical Nanoparticles, Nanorods, and Atomically Precise Nanoclusters

Wang¹,

Shen

et al. 2022

Nanomaterials

View full text Add to dashboard Cite

Cancer is a major global health issue and is a leading cause of mortality. It has been documented that various conventional treatments can be enhanced by incorporation with nanomaterials. Thanks to their rich optical properties, excellent biocompatibility, and tunable chemical reactivities, gold nanostructures have been gaining more and more research attention for cancer treatment in recent decades. In this review, we first summarize the recent progress in employing three typical gold nanostructures, namely spherical Au nanoparticles, Au nanorods, and atomically precise Au nanoclusters, for cancer diagnostics and therapeutics. Following that, the challenges and the future perspectives of this field are discussed. Finally, a brief conclusion is summarized at the end.

show abstract

Section: Gold Nanostructures For Cancer Treatmentmentioning

confidence: 99%

Engineering Gold Nanostructures for Cancer Treatment: Spherical Nanoparticles, Nanorods, and Atomically Precise Nanoclusters

Wang¹,

Shen

et al. 2022

Nanomaterials

View full text Add to dashboard Cite

show abstract

“…Due to the excessive expression of receptors, targeting becomes easy. Ligands carry out the functionalization through active targeting (this has to be deleted) [27].…”

Section: Receptor Approaches Of Drug Targeting In Cancermentioning

confidence: 99%

Targeted Cancer Therapy Using Nanoparticles and Antibody Fragments

Bhattacharya¹,

Gore²

2021

Advances in Precision Medicine Oncology

View full text Add to dashboard Cite

Cancer is caused by an uncontrolled cell division, forming a tumor capable of metastasis. Cancer is the second leading cause of death worldwide. Conventional treatments kill healthy cells, causing side effects. Recently, nanomaterials are explored due to properties such as as- nano-size, high loading, and ligands’ attachment for a selective delivery. Apart from normal body cells, cancer cells express many receptors in excess, which serve as ‘targets’ for attacking the cells. Various ligands like proteins, peptides, polysaccharides can be attached to nanoparticles to allow proper and specific reach to the tumor. Such nanoparticles go to their desired site and stick onto the receptors, taken inside the cells by various methods. Antibodies are natural proteins that bind to foreign substances and remove them. IgG being the most explored antibody, suffers from many disadvantages such as non-specificity for required antigen, limited binding sites, low tumor penetration. Hence many researchers experimented by removing and adjusting the binding sites, using only the binding sites, enhancing the valency of naturally available IgG. It gave many benefits such as enhanced penetration, reduced immunogenicity, better delivery of drugs with fewer side effects. Continuing advancements in the field of protein engineering will help scientists to come up with better solutions. The properties allow easy surface interaction and entry, achieve better biodistribution, and reduce the amount of drug required. Targeting is based on Paul Ehrlich’s ‘magic bullet, ‘where the therapeutic moiety has two parts-one to identify the target and the second to eliminate it. This concept is revised to incorporate a third component, a carrier. Many nanocarriers can be used to target cancer cells containing ligands to identify malignant cells. Approaches to targeting are passive, active and physical targeting. Many such nanoparticles are in clinical trials and can be a better solution to cancer therapy.

show abstract

“…The implementation of these GNPs in combating cancer could be demonstrated through their photothermal capability. Various review articles have comprehensively detailed the concept, applications, safety, heating and cells-death mechanisms, synthesis and morphology, in vitro and in vivo efficacy, and physicochemical properties of these therapies (120)(121)(122)(123)(124)(125)(126)(127). However, the basic principles of this approach are summarized and illustrated in this section to provide the reader with brief outlines of this potential field.…”

Section: Future Perspectives Through Nanotechnologymentioning

confidence: 99%

Biotherapeutic Antibodies for the Treatment of Head and Neck Cancer: Current Approaches and Future Considerations of Photothermal Therapies

Qaraghuli

2020

Front. Oncol.

View full text Add to dashboard Cite

Head and neck cancer (HNC) is a heterogeneous disease that includes a variety of tumors originating in the hypopharynx, oropharynx, lip, oral cavity, nasopharynx, or larynx. HNC is the sixth most common malignancy worldwide and affects thousands of people in terms of incidence and mortality. Various factors can trigger the development of the disease such as smoking, alcohol consumption, and repetitive viral infections. HNC is currently treated by single or multimodality approaches, which are based on surgery, radiotherapy, chemotherapy, and biotherapeutic antibodies. The latter approach will be the focus of this article. There are currently three approved antibodies against HNCs (cetuximab, nivolumab, and pembrolizumab), and 48 antibodies under development. The majority of these antibodies are of humanized (23 antibodies) or human (19 antibodies) origins, and subclass IgG1 represents a total of 32 antibodies. In addition, three antibody drug conjugates (ADCs: telisotuzumab-vedotin, indatuximab-ravtansine, and W0101) and two bispecific antibodies (GBR 1372 and ABL001) have been under development. Despite the remarkable success of antibodies in treating different tumors, success was limited in HNCs. This limitation is attributed to efficacy, resistance, and the appearance of various side effects. However, the efficacy of these antibodies could be enhanced through conjugation to gold nanoparticles (GNPs). These conjugates combine the high specificity of antibodies with unique spectral properties of GNPs to generate a treatment approach known as photothermal therapy. This approach can provide promising outcomes due to the ability of GNPs to convert light into heat, which can specifically destroy cancer cells and treat HNC in an effective manner.

show abstract

Combinational Chemotherapy and Photothermal Therapy Using a Gold Nanorod Platform for Cancer Treatment

Cited by 29 publications

References 128 publications

Engineering Gold Nanostructures for Cancer Treatment: Spherical Nanoparticles, Nanorods, and Atomically Precise Nanoclusters

Engineering Gold Nanostructures for Cancer Treatment: Spherical Nanoparticles, Nanorods, and Atomically Precise Nanoclusters

Targeted Cancer Therapy Using Nanoparticles and Antibody Fragments

Biotherapeutic Antibodies for the Treatment of Head and Neck Cancer: Current Approaches and Future Considerations of Photothermal Therapies

Contact Info

Product

Resources

About